Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17459629 | 0.89 | MEN1 (0.33) | MEN1ALDH1A1CYP2C19KMT2ALMNA | |
| SCHEMBL17459592 | 0.89 | MEN1 (0.33) | MEN1ALDH1A1CYP2C19KMT2ALMNA | |
| SCHEMBL26026678 | 0.88 | GPR119 (0.31) | GPR119 | |
| SCHEMBL20745149 | 0.82 | MEN1 (0.34) | GPR119MEN1ALDH1A1CYP2C19KMT2A | |
| SCHEMBL1134280 | 0.81 | GPR119 (0.33) | GPR119 | |
| SCHEMBL1134398 | 0.80 | GPR119 (0.33) | GPR119ALDH1A1CYP2C19LMNAMAPK1 | |
| SCHEMBL732476 | 0.80 | GPR119 (0.41) | GPR119MEN1ALDH1A1CYP2C19KMT2A | |
| SCHEMBL1134386 | 0.79 | GPR119 (0.33) | GPR119CTSS | |
| SCHEMBL1134397 | 0.78 | GPR119 (0.32) | GPR119 | |
| SCHEMBL1134377 | 0.77 | SMN1; SMN2 (0.35) | GPR119ALDH1A1KMT2ALMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4252848-A2 | OXYSTEROLS AND METHODS OF USE THEREOF | Sage Therapeutics, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20230159517-A1 | CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME LLC (US) | 2023-05-25 | — | — | US | disclosed |
| EP-3529257-B1 | OXYSTEROLS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS INC (US) | 2023-05-10 | — | — | EP | disclosed |
| US-20210380631-A1 | OXYSTEROLS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2021-12-09 | — | — | US | disclosed |
| US-11149054-B2 | Oxysterols and methods of use thereof | SAGE THERAPEUTICS, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-10947216-B2 | Amide compounds and method for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20190248829-A1 | OXYSTEROLS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. (US) | 2019-08-15 | — | — | US | disclosed |
| WO-2018075699-A1 | OXYSTEROLS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| US-20140350051-A1 | Dual Modulators Of 5HT2A and D3 Receptors | HOFFMAN-LA ROCHE INC. | 2014-11-27 | — | — | US | disclosed |
| US-8829029-B2 | Dual modulators of 5HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2014-09-09 | — | — | US | disclosed |
| WO-2010037723-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010037723-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2010-04-08 | — | — | WO | disclosed |
| WO-2009019174-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | WO | disclosed |
| WO-2009019174-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | WO | disclosed |
| US-20090042943-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HOFFMANN-LA ROCHE, INC. | 2009-02-12 | — | — | US | disclosed |
| US-20090042943-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HOFFMANN-LA ROCHE, INC. | 2009-02-12 | — | — | US | disclosed |
| US-20090042943-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HOFFMANN-LA ROCHE, INC. | 2009-02-12 | — | — | US | disclosed |
| US-20090029977-A1 | DUAL MODULATORS OF 5HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | US | disclosed |
| WO-2008119717-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119717-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947216-B2 | Amide compounds and method for making and using | IRAK1, IRAK2, IRAK3 | GPR119 426/4885MEN1 4580/4885ALDH1A1 1076/4885 |
| US-20230159517-A1 | CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | TCOF1, SLC10A2, PAM | GPR119 3158/4885MEN1 77/4885ALDH1A1 4179/4885 |
| US-20090042943-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HTR2A, HTR3A, HTR5A | GPR119 215/4885MEN1 4315/4885ALDH1A1 508/4885 |
| US-20210380631-A1 | OXYSTEROLS AND METHODS OF USE THEREOF | NR1H3, NR1H2, HSD17B7 | GPR119 99/4885MEN1 1778/4885ALDH1A1 304/4885 |
| US-20190248829-A1 | OXYSTEROLS AND METHODS OF USE THEREOF | NR1H3, NR1H2, HSD17B7 | GPR119 100/4885MEN1 1721/4885ALDH1A1 305/4885 |
| US-11149054-B2 | Oxysterols and methods of use thereof | NR1H3, NR1H2, HSD17B7 | GPR119 100/4885MEN1 1721/4885ALDH1A1 305/4885 |
| US-20140350051-A1 | Dual Modulators Of 5HT2A and D3 Receptors | HTR2A, HTR3A, HTR1A | GPR119 134/4885MEN1 3327/4885ALDH1A1 1003/4885 |
| US-20090029977-A1 | DUAL MODULATORS OF 5HT2A AND D3 RECEPTORS | HTR2A, HTR3A, HTR1A | GPR119 134/4885MEN1 3327/4885ALDH1A1 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.